Dapagliflozin in STEMI
The University of Ottawa Dapagliflozin in STEMI Randomized Clinical Trial
Ottawa Heart Institute Research Corporation
256 participants
Jan 20, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dapagliflozin 10 mg daily X 7 days
CMR 3-5 days post randomization
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06174753